$IBIO

iBio stock initiated at buy by H.C. Wainwright with $7 target

H.C. Wainwright initiated coverage on iBio Inc. (NASDAQ:IBIO) with a buy rating and a $7.00 price target, citing potential in its obesity and diabetes treatments. The stock has declined 52% over six months. The firm highlighted the company's cash position of $88.0 million as of June 30, 2026, with runway extending into 2028, despite high cash burn.

Original reporting
Published Sep 17, 2026, 11:56 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 12:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$IBIO
Bullish
medium confidence
Mentioned
$IBIO
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$IBIOBullishHigh
01

Why it matters

New coverage could attract institutional and retail interest, supporting price appreciation.

02

Market read

Analyst upgrade may influence micro‑cap biotech sentiment.

03

What to watch

Potential dilution from future financing needs.

Relevance 6/10Novelty 7/10Timing: today

Background

Analyst coverage initiation with buy rating and price target for iBio.

Company-level read

Ticker impact

$IBIOBullishMedium confidence
Context

H.C. Wainwright initiated coverage on iBio with a buy rating and a $7 price target, citing pipeline potential.

Expected impact

Potential upside toward $7 target over the next weeks.

Evidence & confidence

Buy rating and significant upside from current price suggest traders may add positions.

Market effects

Highlights growing interest in obesity and metabolic disease therapeutics.

Limited to US biotech sector.

Modest, as iBio is a micro‑cap biotech.

Counterpoint

Target may be overly optimistic given cash burn and early‑stage data.

Key entities

  • iBio Inc.

    Biotech firm developing obesity and metabolic disease therapies.

  • H.C. Wainwright

    Equity research firm that initiated coverage.

Related articles

$IBIOMed

iBio, Inc. (IBIO): Results of Operations and Financial Condition

iBio, Inc. (IBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update SAN DIEGO, August 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic an

$IBIOMedAI 9/10

iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity

iBio (NASDAQ: IBIO) said it dosed the first participant in a Phase 1 trial of IBIO-600, its first obesity/cardiometabolic program to enter human testing. The randomized, double-blind, placebo-controlled single-ascending-dose study will assess safety, tolerability, PK/PD and body-composition effects in ~32 adults with overweight/obesity, with completion expected in 2H 2027.

$NIOMed

NIO Stock Eyes End To 5-Week Slump: Retail Loads Up As Onvo Hits 200,000 Deliveries, Battery Swaps Smash Record

NIO reported 4,165 battery swap stations and 5,376 charging stations in China, with 86.7% of energy delivered to non-NIO vehicles. The company aims to add 1,000 swap stations this year, with Geely Holding Group investing $2.4B in NIO Power. Onvo, a partner brand, has launched new models and expanded service centers. Retail investors on Stocktwits expressed bullish sentiment, with NIO shares down 31% YTD.

$NVDAMed

Dan Ives Names 5 Tech Stocks for 2027, Including One That Doubled in 2026

Dan Ives, a partner at Yorkville Ives, named Nvidia, Microsoft, Palantir, Apple, and CrowdStrike as his top tech stock picks for 2027. He highlighted a $4 trillion AI spending wave and set price targets: Nvidia ($300), Microsoft ($615), Palantir ($250), Apple ($400), and CrowdStrike ($335). The stocks have varied performance in 2026, with CrowdStrike up 126.50% and others showing modest gains.